WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012041018) ANTI TNF α HUMANIZED ANTIBODY AND FRAGMENT ANTIGEN BINDING (FAB) AND USE THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/041018    International Application No.:    PCT/CN2011/001668
Publication Date: 05.04.2012 International Filing Date: 30.09.2011
IPC:
C07K 16/24 (2006.01), C12N 15/13 (2006.01), A61K 39/395 (2006.01), A61P 37/02 (2006.01)
Applicants: CHENGDU KANGHONG BIOTECHNOLOGIES CO., LTD. [CN/CN]; No.36 Shuxi Rd., Jinniu Dis. ChengDu, Sichuan 610036 (CN) (For All Designated States Except US).
KE, Xiao [CN/CN]; (CN) (For US Only).
GAO, Xiaoping [CN/CN]; (CN) (For US Only)
Inventors: KE, Xiao; (CN).
GAO, Xiaoping; (CN)
Agent: JEEKAI & PARTNERS; Suite 602, Jinyu Tower A129 West Xuan Wu Men Street XiCheng District, Beijing 100031 (CN)
Priority Data:
201010297255.0 30.09.2010 CN
Title (EN) ANTI TNF α HUMANIZED ANTIBODY AND FRAGMENT ANTIGEN BINDING (FAB) AND USE THEREOF
(FR) ANTICORPS HUMANISÉ ANTI-TNF Α ET FRAGMENT DE LIAISON À L'ANTIGÈNE (FAB) ET LEUR UTILISATION
(ZH) 抗TNFα的人源化抗体及其抗原结合片段Fab和用途
Abstract: front page image
(EN)Disclosed are an anti human tumor necrosis factor α humanized antibody and a fragment antigen binding (Fab) thereof. The disclosure includes a composition for the antibody or the fragment antigen binding (Fab), and the use of the antibody or fragment antigen binding (Fab) in treating diseases related to tumor necrosis factor α.
(FR)La présente invention concerne un anticorps antihumain humanisé dirigé contre le facteur de nécrose tumorale α et son fragment de liaison à l'antigène (Fab). L'invention concerne également une composition pour l'anticorps ou le fragment de liaison à l'antigène (Fab), et l'utilisation de l'anticorps ou du fragment de liaison à l'antigène (Fab) dans le traitement de maladies liées au facteur de nécrose tumorale α.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)